Tools

LEADER 03205cam a22005174a 4500

001 ocn156863742;

003 OCoLC;

005 20141212021320.0;

008 070718s2008 nyu b 001 0 eng ;

010 a| 2007029727;

016 7 a| 1013121422| DNLM;

020 a| 9780826129345 (alk. paper) :c| $44.00;

020 a| 082612934X (alk. paper);

029 1 a| NLMb| 101312142;

035 a| (Sirsi) o156863742;

035 a| (OCoLC)370810346;

042 a| pcc;

043 a| n-us---;

049 a| NEHH;

100 1 a| Breggin, Peter Roger,d| 1936-=| ^A9817;

245 10 a| Brain-disabling treatments in psychiatry :b| drugs, electroshock, and the psychopharmaceutical complex /c| Peter R. Breggin.;

250 a| 2nd ed.;

300 a| xxx, 546 pages ;c| 24 cm;

336 a| text2| rdacontent;

337 a| unmediated2| rdamedia;

338 a| volume2| rdacarrier;

504 a| Includes bibliographical references (p. 463-526) and index.;

505 0 a| The brain-disabling, spellbinding effects of psychiatric drugs -- Deactivation syndrome (chemical lobotomy) caused by neuroleptics -- neuroleptic-induced anguish, including agitation, despair, and depression -- Severe and potentially irreversible neurological syndromes (tardive dyskinesia and neuroleptic malignant syndrome) caused by neuroleptics -- Neuroleptic-induced neurotoxicity, brain damage, persistent cognitive deficits, dementia, and psychosis -- Recent developments in antidepressant label changes -- Antidepressant-induced mental, behavioral, and cerebral abnormalities -- Lithium and other drugs for bipolar disorder -- Electroconvulsive therapy (ECT) for depression -- From attention-deficit/hyperactivity disorder (ADHD) to bipolar disorder : diagnosing America's children -- Stimulant-induced brain damage, brain dysfunction, and psychiatric adverse reactions -- Antianxiety drugs, including behavioral abnormalities caused by Xanax and Halcion -- The Food and Drug Administration (FDA) and the National Institute of Mental Health (NIMH) : drug company advocates -- Drug company deceptions -- How to more safely stop taking psychiatric drugs -- Failed promises, last resorts, and psychotherapy.;

610 10 a| United States.b| Food and Drug Administration.=| ^A1253;

650 0 a| Psychotropic drugsx| Side effects.=| ^A9581;

650 0 a| Brainx| Effect of drugs on.=| ^A990461;

650 0 a| Electroconvulsive therapyx| Complications.=| ^A9690;

650 0 a| Iatrogenic Disease.?| UNAUTHORIZED;

650 12 a| Mental Disordersx| therapyz| United States.=| ^A917798;

650 22 a| Brain Damage, Chronicx| etiologyz| United States.=| ^A954073;

650 22 a| Drug Industryz| United States.=| ^A917640;

650 22 a| Electroconvulsive Therapyx| adverse effectsz| United States.=| ^A957537;

650 22 a| Psychotropic Drugsx| adverse effectsz| United States.=| ^A920483;

994 a| C0b| NEH;

919 a| BOOK;

096 a| WM 400 B833b 2008;

596 a| 4;

998 a| 1577920;

999 a| WM 400 B833B 2008w| NLMc| 1i| 31740005257047d| 6/20/2013e| 5/23/2013f| 2/28/2011g| 1l| HSLBKm| HSLn| 5p| $44.00r| Ys| Yt| HBKu| 3/5/2008x| BOOKz| HSTACKSo| .STAFF. 0;

Brain-disabling treatments in psychiatry : drugs, electroshock, and the psychopharmaceutical complex / Peter R. Breggin.

Author/creator	Breggin, Peter Roger, 1936-
Format	Book
Edition	2nd ed.
Publication Info	New York : Springer Pub., ©2008.
Description	xxx, 546 pages ; 24 cm
Subjects	United States. Food and Drug Administration. Psychotropic drugs--Side effects. Brain--Effect of drugs on. Electroconvulsive therapy--Complications. Iatrogenic Disease. Mental Disorders--therapy. --United States. Brain Damage, Chronic--etiology. --United States. Drug Industry--United States. Electroconvulsive Therapy--adverse effects. --United States. Psychotropic Drugs--adverse effects. --United States.

Contents	The brain-disabling, spellbinding effects of psychiatric drugs -- Deactivation syndrome (chemical lobotomy) caused by neuroleptics -- neuroleptic-induced anguish, including agitation, despair, and depression -- Severe and potentially irreversible neurological syndromes (tardive dyskinesia and neuroleptic malignant syndrome) caused by neuroleptics -- Neuroleptic-induced neurotoxicity, brain damage, persistent cognitive deficits, dementia, and psychosis -- Recent developments in antidepressant label changes -- Antidepressant-induced mental, behavioral, and cerebral abnormalities -- Lithium and other drugs for bipolar disorder -- Electroconvulsive therapy (ECT) for depression -- From attention-deficit/hyperactivity disorder (ADHD) to bipolar disorder : diagnosing America's children -- Stimulant-induced brain damage, brain dysfunction, and psychiatric adverse reactions -- Antianxiety drugs, including behavioral abnormalities caused by Xanax and Halcion -- The Food and Drug Administration (FDA) and the National Institute of Mental Health (NIMH) : drug company advocates -- Drug company deceptions -- How to more safely stop taking psychiatric drugs -- Failed promises, last resorts, and psychotherapy.
Bibliography note	Includes bibliographical references (p. 463-526) and index.
LCCN	2007029727
ISBN	9780826129345 (alk. paper) :
ISBN	082612934X (alk. paper)

Availability

Library	Location	Call Number	Status	Item Actions
Laupus	Books - Stacks	WM 400 B833B 2008	✔ Available	Place Hold

Brain-disabling treatments in psychiatry : drugs, electroshock, and the psychopharmaceutical complex / Peter R. Breggin.

Click here for more information about this title

Availability